Tech Support

TECHNICAL SUPPORT
+1.800.674.3430

This line is for technical support.
For General Enquiries please click General Contact

SYMPOSIUM: Taking Immunotherapies to the Next Level

November 7, 2019 - Paris, France

Crown Bioscience invites you to attend our Paris symposium focused on Taking Immunotherapies to the Next Level. Join the discussion on how to improve humanised preclinical models, develop the best strategies in optimising syngeneic translational relevance, and how to apply organoids to I/O research and drug development.

WEBINAR: Applications of HUB Tumor Organoids in Oncology Drug Discovery

Wednesday November 13, 2019 - 4am/10am/5pm ET

Presented by Dr Rajendra Kumari this webinar will discuss the drug discovery applications of HUB tumor organoids including large scale drug screening, in vivo model selection, and in silico drug discovery. She'll also explore how to improve predictivity in drug development with our unique matched in vitro PDXO/in vivo PDX pairs.

Review our 9 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Posters

Preview our poster topics now covering a wide variety of preclinical oncology and immuno-oncology platforms including tumor organoids for drug discovery and I/O drug development, orthotopic syngeneic models, and immunoprofiling data.

NEW WHITE PAPER! HUB Organoid Technology: Advantages in 3D In Vitro Modeling

Review the breakthrough discoveries leading to the development of HUB Organoids. Explore the key features of these 3D in vitro models including organ morphology recapitulation, stability, genomic superiority, and long-term culture, as well as their main utilities in research and development.

ON DEMAND WEBINAR: How to Detect, Characterize, and Evaluate CAR-T Cell Therapies

Presented by Dr Rajendra Kumari this webinar explores how to overcome translational challenges in CAR-T cell therapy development. Learn more on the different preclinical models available for CAR-T and cell therapy efficacy and safety assessment including PDX, as well as a novel rare cell analysis platform for sensitive CAR-T detection.

ON DEMAND WEBINAR: Preclinical Obesity Research: Best Practice in Model Selection and Study Design

Presented by Dr Fred Beasley this webinar explores how to select the most appropriate models for your preclinical obesity studies, including polygenic vs monogenic models and recommendations based on drug modes of action. We also review best practice in obesity study design to maximize data outcomes.

ON DEMAND WEBINAR: Demonstrating Clinical Relevance in 3D In Vitro Modeling with HUB Organoids

Presented by Dr Sylvia Boj, Hubrecht Organoid Technology this webinar reviews the development and application of HUB Organoids. Explore the many advantages of HUB Organoids within 3D in vitro modeling, including direct clinical relevance and immuno-oncology applications.

NEW WHITE PAPER: How to Assess Immunotherapy Toxicity using NHPs

Learn more about NHPs as a valuable early-stage preclinical platform for non-GLP exploratory toxicology studies. Explore the robust data these studies generate in a rapid, flexible, and cost-effective manner to assess immunotherapy safety and de-risk future clinical trials.

WHITE PAPER: Optimizing Translational IBD Capabilities How to Select the Right Preclinical Model

Explore the key features of commonly used preclinical IBD models, including model development and example treatment studies. Learn how to choose the most appropriate model for your drug development program, based on drug target and mechanism of action alongside model disease pathogenesis and clinical relevance.

CVMD

Models of Obesity

obesity-img.jpg

CrownBio’s preclinical Translational Technology Platforms provide spontaneous & diet-induced obesity (DIO) models, to support the transition of new agents into the clinic.

Learn More

Oncology

Oncology Databases

databases-img.jpg

Our unique databases provide a curated source of well-characterized models available to use for drug discovery including PDX models, cell lines, and syngeneic models.

Learn More

CVMD

Diabetes Models

oncoexpress-img.jpg

Models of both Type 1 and Type 2 diabetes, including conventional, as well as unique, highly translatable models for in vivo efficacy studies of antidiabetic agents.

Learn More

Latest from our Blog

October 4, 2019

What are PDX-Derived Organoids (PDXOs)?

Learn about PDX-derived organoids, including PDXO establishment and utility in a pioneering drug discovery platform combining the benefits of in vitro PDXO and highly predictive in vivo PDX models.

Read More

October 4, 2019

What are PDX-Derived Organoids (PDXOs)?

Learn about PDX-derived organoids, including PDXO establishment and utility in a pioneering drug...

Read More

September 27, 2019

Preclinical Obesity Study Design: Top 10 Questions

Review the top 10 questions on optimizing preclinical obesity studies and model selection from...

Read More

September 19, 2019

Key Discoveries in the Development of Modern HUB Organoids

Learn about the key research discoveries leading to the development of modern HUB Organoids.

Read More

September 17, 2019

Targeting Tumor-Associated Antigens and Tumor-Specific Antigens

Learn more about targeting human tumor-associated antigens (TAAs) or tumor-specific antigens...

Read More

September 13, 2019

HUB Tumor Organoids: Top 15 Questions

Review the key questions on HUB tumor organoids from our recent webinar, answered by Dr Sylvia...

Read More

Upcoming Events


October 26 - 30, 2019 | Booth #410

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Boston, MA


November 6 - 10, 2019

SITC 2019

National Harbor, MD


November 7, 2019

Symposium: Taking Immunotherapies to the Next Level

Paris, France


November 8, 2019

2019 NC3Rs Meeting

London, UK


November 13, 2019

Webinar: Applications of HUB Tumor Organoids in Oncology Drug Discovery